Hot Keywords
non-alcoholic fatty liver disease epidemiology microenvironment nonalcoholic steatohepatitis transplantation cholangiocarcinoma direct-acting antiviral immunotherapy hepatitis B hepatitis C liver resection imaging cancer stem cell diagnosis gene cirrhosis biomarker recurrence

Topic: Hepatocellular Carcinoma and Related Potential Immunotherapy with Focus on HBV-induced HCC

A special issue of Hepatoma Research

ISSN 2454-2520 (Online), ISSN 2394-5079 (Print)

Submission deadline: 30 Nov 2022

Guest Editor(s)

  • Pil Soo Sung, MD
    Division of Hepatology, Department of Internal Medicine, The Catholic University of Korea, Seoul, Korea.

    Website | E-mail

  • Sung won Lee, MD
    Division of Hepatology, Department of Internal Medicine, The Catholic University of Korea, Seoul, Korea.

    Website | E-mail

Special Issue Introduction

In the tumor microenvironment (TME) of HCC, the various types of innate and innate-like cells such as natural killer (NK) cells, helper innate lymphoid cells, natural killer T (NKT) cells, mucosal-associated invariant T cells (MAITs), gamma delta T cells, tumor-associated macrophages (TAMs), granulocytes, and dendritic cells (DCs) contribute to the homeostasis of anti-tumor immune responses. Some of these cells can increase or inhibit the anticancer immune response and can have positive or negative implications for immunotherapy, as the liver is involved in immunity as well as in immune tolerance. Recently, nivolumab was approved as second-line therapy for advanced HCC management, and atezolizumab plus bevacizumab was recently shown to be superior to sorafenib as primary treatment for advanced HCC. Responses to immune-based therapies are critically shaped by the TME in HCC. It is demonstrably impeded by the accretion of immunosuppressive cells, including MDSCs, regulatory T-cells (Tregs), TAMs and neutrophils, thereby resulting in unfavorable prognoses. To enhance the efficacy of immune-based therapy in HCC, these immunosuppressive cells should be deleted or undergo phenotype changes. In HBV-induced HCC, recent studies demonstrated that immunosuppressive PD-L1+ TAMs play critical roles in blocking efficient anti-tumor immune responses, whereas HBV-specific, liver-resident memory T cells show anti-tumor activity.

In this special issue, following topics may be included.

1. Tumor-associated macrophages in HBV-induced HCC
2. HBV-specific T cell response and HBV-induced HCC
3. Immune imbalance leading to HCC in HBV-infected liver
4. NK cells or other innate-like immune cells in HBV-induced HCC
5. Biomarkers for immunotherapy in HCC
6. Immunotherapy-based combination treatment strategy for HCC
7. Sequential treatment strategy including immunotherapy for HCC
8. Adjuvant immunotherapy following curative treatment for HCC
9. Current limits and future perspectives of immunotherapy for HCC

Submission Deadline

30 Nov 2022

Submission Information

Articles of special issue are free of charge for article processing.
For Author Instructions, please refer to
For Online Submission, please login at
Submission Deadline: 31 May 2022
Contacts: Paula Dong, Assistant Editor,

Published Articles

© 2016-2022 OAE Publishing Inc., except certain content provided by third parties